PAR4 (Protease-Activated Receptor 4) PARticularly Important 4 Antiplatelet Therapy

被引：25

作者：

Han, Xu ^{[1
]}

Nieman, Marvin T. ^{[1
]}

机构：

[1] Case Western Reserve Univ, Dept Pharmacol, 10900 Euclid Ave, Cleveland, OH 44106 USA

来源：

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY | 2018年 / 38卷 / 02期

基金：

美国国家卫生研究院;

关键词：

THROMBIN-RECEPTOR; SECONDARY PREVENTION; VORAPAXAR; INHIBITION; ANTAGONIST;

D O I：

10.1161/ATVBAHA.117.310550

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：287 / 289

页数：3

共 19 条

[1] Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee Meeting About Vorapaxar [J].

Baker, Nevin C. ;

Lipinski, Michael J. ;

Lhermusier, Thibault ;

Waksman, Ron .

CIRCULATION, 2014, 130 (15) :1287-1294

[2] Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation [J].

Covic, L ;

Misra, M ;

Badar, J ;

Singh, C ;

Kuliopulos, A .

NATURE MEDICINE, 2002, 8 (10) :1161-1165

[3] Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood [J].

French, S. L. ;

Arthur, J. F. ;

Lee, H. ;

Nesbitt, W. S. ;

Andrews, R. K. ;

Gardiner, E. E. ;

Hamilton, J. R. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2016, 14 (08) :1642-1654

[4] Protease-activated receptor-4 uses dual prolines and an anionic retention motif for thrombin recognition and cleavage [J].

Jacques, SL ;

Kuliopulos, A .

BIOCHEMICAL JOURNAL, 2003, 376 (03) :733-740

[5] Substrate-assisted catalysis of the PAR1 thrombin receptor - Enhancement of macromolecular association and cleavage [J].

Jacques, SL ;

LeMasurier, M ;

Sheridan, PJ ;

Seeley, SK ;

Kuliopulos, A .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (52) :40671-40678

[6] Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin [J].

Kahn, ML ;

Nakanishi-Matsui, M ;

Shapiro, MJ ;

Ishihara, H ;

Coughlin, SR .

JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (06) :879-887

[7] Vorapaxar in the Secondary Prevention of Atherothrombotic Events [J].

Morrow, David A. ;

Braunwald, Eugene ;

Bonaca, Marc P. ;

Ameriso, Sebastian F. ;

Dalby, Anthony J. ;

Fish, Mary Polly ;

Fox, Keith A. A. ;

Lipka, Leslie J. ;

Liu, Xuan ;

Nicolau, Jose Carlos ;

Ophuis, A. J. Oude ;

Paolasso, Ernesto ;

Scirica, Benjamin M. ;

Spinar, Jindrich ;

Theroux, Pierre ;

Wiviott, Stephen D. ;

Strony, John ;

Murphy, Sabina A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (15) :1404-1413

[8] Targeting the anionic region of human protease-activated receptor 4 inhibits platelet aggregation and thrombosis without interfering with hemostasis [J].

Mumaw, M. M. ;

De La Fuente, M. ;

Noble, D. N. ;

Nieman, M. T. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 (08) :1331-1341

[9] Interaction of thrombin with PAR1 and PAR4 at the thrombin cleavage site [J].

Nieman, Marvin T. ;

Schmaier, Alvin H. .

BIOCHEMISTRY, 2007, 46 (29) :8603-8610

[10] Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial [J].

Scirica, Benjamin M. ;

Bonaca, Marc P. ;

Braunwald, Eugene ;

De Ferrari, Gaetano M. ;

Isaza, Daniel ;

Lewis, Basil S. ;

Mehrhof, Felix ;

Merlini, Piera A. ;

Murphy, Sabina A. ;

Sabatine, Marc S. ;

Tendera, Michal ;

Van de Werf, Frans ;

Wilcox, Robert ;

Morrow, David A. .

LANCET, 2012, 380 (9850) :1317-1324

← 1 2 →